Third Class Of Drugs Likely To Limit, Not Expand Access – Former NDAC Chair
This article was originally published in The Tan Sheet
Executive Summary
"Very limited data" has been generated to prove a third class of drugs will improve access to products and benefit public health, according to a former Nonprescription Drug Advisory Committee chairman
You may also be interested in...
FDA Third Class Thoughts Expected In Months; Agency Wants Industry Input
FDA will include industry in the process of developing distribution channels between traditional Rx and OTC spaces, agency representatives told attendees of Consumer Healthcare Products Association's Regulatory and Scientific Conference
FDA Third Class Thoughts Expected In Months; Agency Wants Industry Input
FDA will include industry in the process of developing distribution channels between traditional Rx and OTC spaces, agency representatives told attendees of Consumer Healthcare Products Association's Regulatory and Scientific Conference
FDA Third Class Thoughts Expected In Months; Agency Wants Industry Input
FDA will include industry in the process of developing distribution channels between traditional Rx and OTC spaces, agency representatives told attendees of Consumer Healthcare Products Association's Regulatory and Scientific Conference